Ticker Details
Amylyx Pharmaceuticals, Inc.
IPO Date:	January 7, 2022
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.31B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.59 | 3.94%
Avg Daily Range (30 D):	$1.31 | 5.81%
Avg Daily Range (90 D):	$0.77 | 4.04%

Institutional Daily Volume
Avg Daily Volume:	1.21M
Avg Daily Volume (30 D):	2.71M
Avg Daily Volume (90 D):	1.65M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	83
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	2,004
Avg Institutional Trade:	$1.91M
Avg Institutional Trade (30 D):	$2.45M
Avg Institutional Trade (90 D):	$2.28M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.52M
Avg Closing Trade (30 D):	$6.13M
Avg Closing Trade (90 D):	$3.82M
Avg Closing Volume:	162.98K

News

Feb 19, 2026 @ 8:30 AM Global Amyotrophic Lateral Sclerosis Therapeutics ... Source: Custom Market Insights

Aug 28, 2025 @ 5:00 PM Antisense Oligonucleotide Therapeutics Clinical Tr... Source: Delveinsight

Jul 14, 2025 @ 10:26 PM AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Inves... Source: Bragar Eagel & Squire, P.C.

Jul 8, 2025 @ 1:00 AM AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Inves... Source: Bragar Eagel & Squire, P.C.

Oct 18, 2024 @ 11:26 AM Why Amylyx Pharmaceuticals Stock Was So Healthy Th... Source: Eric Volkman

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.41	$-.39	$-.37
Diluted EPS	$-1.41	$-.39	$-.37
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-152.09M	$-43.42M	$-41.28M
Operating Income / Loss	$-162.1M	$-45.69M	$-43.78M
Cost of Revenue
Net Cash Flow	$-9.22M	$-179.81M	$2.49M
PE Ratio